SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc., (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, today announced it has entered into an $8.4 million Common Stock Purchase Agreement with Fusion Capital Fund II, LLC, a Chicago-based institutional investor. Under the agreement, the Company has agreed to sell to Fusion Capital $400,000 of its common stock on the date that a registration statement related to the transaction is filed with the Securities and Exchange Commission (SEC). The Company may sell an additional $8.0 million of common stock to Fusion Capital from time to time over a 25-month period after the SEC has declared effective the registration statement related to the transaction. The proceeds will be used to advance the commercialization of Aethlon’s Hemopurifier® treatment technology.
